These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 15784340

  • 1. The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration.
    Forsberg MM, Huotari M, Savolainen J, Männistö PT.
    Eur J Pharm Sci; 2005 Apr; 24(5):503-11. PubMed ID: 15784340
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.
    Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Järvinen T, Männistö PT.
    J Pharmacol Exp Ther; 2003 Feb; 304(2):498-506. PubMed ID: 12538800
    [Abstract] [Full Text] [Related]

  • 3. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
    Napolitano A, Bellini G, Borroni E, Zürcher G, Bonuccelli U.
    Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
    [Abstract] [Full Text] [Related]

  • 4. Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats.
    Huotari M, Passlin M, Nordberg HL, Forsberg M, Kotisaari S, Tuomisto L, Shintani F, Tanaka KF, Reenilä I, Laitinen K, Männistö PT.
    J Neurosci Methods; 2001 Aug 15; 109(1):47-52. PubMed ID: 11489299
    [Abstract] [Full Text] [Related]

  • 5. Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase.
    Törnwall M, Tuomainen P, Männistö PT.
    Eur J Pharmacol; 1993 Aug 03; 239(1-3):39-45. PubMed ID: 8223912
    [Abstract] [Full Text] [Related]

  • 6. Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase.
    Forester SC, Lambert JD.
    Carcinogenesis; 2014 Feb 03; 35(2):365-72. PubMed ID: 24148818
    [Abstract] [Full Text] [Related]

  • 7. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
    Gerlach M, Xiao AY, Kuhn W, Lehnfeld R, Waldmeier P, Sontag KH, Riederer P.
    J Neural Transm (Vienna); 2001 Feb 03; 108(2):189-204. PubMed ID: 11314772
    [Abstract] [Full Text] [Related]

  • 8. [Microdialysis study of tolcapone effect during blockage of neuronal dopamine reuptake caused by GBR-12909].
    Budygin EA, Gaĭnetdinov RR, Raevskiĭ KS, Li IH, Mannisto PT.
    Eksp Klin Farmakol; 1997 Feb 03; 60(5):8-10. PubMed ID: 9483396
    [Abstract] [Full Text] [Related]

  • 9. Effects of CGP 28014 on the in vivo release and metabolism of dopamine in the rat striatum assessed by brain microdialysis.
    Steulet AF, Stöcklin K, Wicki P, Waldmeier P.
    Neurochem Res; 1993 Nov 03; 18(11):1131-6. PubMed ID: 8255364
    [Abstract] [Full Text] [Related]

  • 10. Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro.
    Gerlach M, Ukai W, Ozawa H, Riederer P.
    J Neural Transm (Vienna); 2002 May 03; 109(5-6):789-95. PubMed ID: 12111468
    [Abstract] [Full Text] [Related]

  • 11. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
    Kaakkola S.
    Int Rev Neurobiol; 2010 May 03; 95():207-25. PubMed ID: 21095464
    [Abstract] [Full Text] [Related]

  • 12. Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes.
    Lautala P, Kivimaa M, Salomies H, Elovaara E, Taskinen J.
    Pharm Res; 1997 Oct 03; 14(10):1444-8. PubMed ID: 9358559
    [Abstract] [Full Text] [Related]

  • 13. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
    Kaakkola S, Gordin A, Männistö PT.
    Gen Pharmacol; 1994 Sep 03; 25(5):813-24. PubMed ID: 7835624
    [Abstract] [Full Text] [Related]

  • 14. Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study.
    Kaakkola S, Wurtman RJ.
    Brain Res; 1992 Aug 07; 587(2):241-9. PubMed ID: 1381981
    [Abstract] [Full Text] [Related]

  • 15. No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats.
    Li YH, Wirth T, Huotari M, Laitinen K, MacDonald E, Männistö PT.
    Eur J Pharmacol; 1998 Sep 04; 356(2-3):127-37. PubMed ID: 9774242
    [Abstract] [Full Text] [Related]

  • 16. Microdialysis studies on the action of tolcapone on pharmacologically-elevated extracellular dopamine levels in conscious rats.
    Huotari M, Gainetdinov R, Männistö PT.
    Pharmacol Toxicol; 1999 Nov 04; 85(5):233-8. PubMed ID: 10608486
    [Abstract] [Full Text] [Related]

  • 17. [Effect of subchronic administration of tolcapone on release of striatum dopamine and its metabolites induced by L-DOPA and carbidopa].
    Budygin EA, Gaĭnetdinov RR, Raevskiĭ KS, Mannisto PT.
    Biull Eksp Biol Med; 1998 Feb 04; 125(2):168-71. PubMed ID: 9559129
    [No Abstract] [Full Text] [Related]

  • 18. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
    Männistö PT, Tuomainen P, Tuominen RK.
    Br J Pharmacol; 1992 Mar 04; 105(3):569-74. PubMed ID: 1628144
    [Abstract] [Full Text] [Related]

  • 19. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase.
    Vieira-Coelho MA, Soares-da-Silva P.
    Brain Res; 1999 Mar 06; 821(1):69-78. PubMed ID: 10064789
    [Abstract] [Full Text] [Related]

  • 20. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.
    Korlipara LV, Cooper JM, Schapira AH.
    Neuropharmacology; 2004 Mar 06; 46(4):562-9. PubMed ID: 14975680
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.